Synthesis and anti-HIV evaluation of the novel 2-(m-Chlorobenzyl)-4- substituted-7-methyl-1, 1, 3-trioxo-pyrazolo[4, 5-e] [1, 2, 4]thiadiazines

Archives of Pharmacal Research

Volumn 29, Issue 11, 2006, Pages 957-962

  Yan, Ren Zhang ^a   Liu, Xin Yong ^a   Xu, Wen Fang ^a   Pannecouque, Christophe ^b   Witvrouw, Myriam ^a   De Clercq, Erik ^a  

^a SHANDONG UNIVERSITY   (China)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

HIV 1; MT 4 cells; NNRTIs; Pyrazolothiadiazines; Synthesis

Indexed keywords

EID: 33845350344     PISSN: 02536269     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02969278     Document Type: Article

References (13)

1. Arranz, M. E., Vega, S., and Díaz, J. A., Synthesis of Hetero [ 1,2,4]thiadiazine 1,1-Dioxides. Heterocycles, 45, 1767-1774 (1997).
2. Arranz M. E., Diaz, J. A., Ingate, S. T., Witvrouw, M., Pannecouque, C., Balzarini, J., De Clercq, E., and Vega, S., Novel 1,1,3-trioxo-2H,4H-thieno[3,4- e][1,2,4]thiadiazine derivatives as non-nucleoside reverse transcriptase inhibitors that inhibit human immunodeficiency virus type 1 replication. J. Med. Chem., 41, 4109-4117 (1998).
3. Arranz, M. E., Díaz, J. A., Ingate, S. T., Witvrouw, M., Pannecouque, C., Balzarini, J., De Clerq, E., and Vega, S., Synthesis and anti-HIV activity of 1,1,3-trioxo-2H,4H-thieno [3,4-e] [1,2,4]thiadiazines (TTDs): a new family of HIV-1 specific non-nucleoside reverse transcriptase inhibitors. Bioorg. Med. Chem., 7, 2811-2822 (1999).
4. Arranz, M. E., Díaz, J. A., Vega, S., Campos-Toimil, M., Orallo, F., Cardelus, I., Llenas, J., and Fernandez, A. G., Synthesis and pharmacological evaluation of 2, 3-dihydro-3-oxo-4H-thieno [3, 4-e][1, 2, 4]thiadiazine 1, 1-dioxidesas voltage-dependent calcium channel blockers. Eur. J. Med. Chem., 35, 751-759 (2000).
5. Das, K., Lewi, P. J., Hughes, S. H., and Arnold, E., Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors. Prog. Biophys. Mol. Biol., 88, 209-231 (2005).
6. De Clercq, E., Recent highlights in the development of new antiviral drugs. Curr Opin Microbiol., 8, 552-560 (2005).
7. Joncckheere, H., Anne, J., and De Clercq, E., The HIV-1 reverse transcription (RT) process as target for RT inhibitors. Med. Res. Rev., 20, 129-154 (2000).
8. Martinez, A., Gil, C., Abasolo, M. I., Castro, A., Bruno, A. M., Perez, C., Prieto, C., and Otero, J., Benzothiadiazine dioxide dibenzyl derivatives as potent human cytomegalovirus inhibitors: Synthesis and comparative molecular field analysis. J. Med. Chem., 43, 3218-3225 (2000a).
9. Martinez, A., Gil, C., Perez, C., Castro, A., Prieto, C., Otero, J., Andrei, G., Snoeck, R., Balzarini, J., and De Clercq E., Nucleoside human cytomegalovirus inhibitors: Synthesis and antiviral evaluation of (chlorophenylmethyl)benzothiadiazine dioxide derivatives. J. Med. Chem., 43, 3267-3273 (2000b).
10. Patani, G. P. and LaVoie, E. J., Bioisosterism: A rational approach in drug design. Chem. Rev., 96, 3147-3176 (1996).
11. Pauwels, R., Balzarini, J., Baba, M., Snoeck, R., Schols, D., Herdewijn, P., Desmyter, J., and De Clercq, E., Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods., 20,309-321 (1988).
12. Schaefer, W., Gunar Friebe, W., Leinert, H., Mertens, A., Poll, T., Vonder Saal, W., Zilch, H., Nuber, B., and L. Ziegler, M., Non-nucleoside inhibitors of HIV-1 reverse transcriptase: molecular modeling and x-ray structure investigations. J. Med. Chem., 36, 726-732 (1993).
13. Witvrouw, M., Arranz, M. E., Pannecouque, C., Declerq, R., Jonckheere, H., Schmit, J. C., Vandamme, A. M., Dia, J. A., Ingate, S. E., Desmyter, J., Esnouf, E., Meervelt, L. V., Vega, S., Bazarni, J., and De Clercq, E., 1,1,3-Trioxo-2H,4H-thieno [e-3,4][1,2,4]thiadiazines (TTDs) derivatives: a new class of nonnucleoside human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitors with anti-HIV-1 activity. Antimicrob. Agents. Chemother., 42, 618 -623 (1998).